◼ Archived
Business
🔮 fades ✓
Retatrutide beats Ozempic on weight loss, blood sugar control, study says
Retatrutide outperforms Ozempic in weight loss and blood sugar control, a recent study claims.
Retatrutide
14 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Retatrutide
This hub groups 14 separate news trends connected to Retatrutide, spanning June 23, 2026 through October 29, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 105 article observations and 99 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly's new weight loss drug retatrutide outperforms Ozempic in head-to-head trial.
◼ Archived
Health
🔮 fades ✓
Triple-action weekly weight-loss drug reduces sleep apnea in two late-stage trials
A leading obesity drug unexpectedly slashes sleep‑apnea events, reshaping expectations for weight‑loss therapies
◼ Archived
Business
🔮 fades ✓
Tests of Unapproved Weight- Loss Drug Reveal Its Dangers
Fatalities and terrifying lab results push an unapproved weight‑loss drug into the spotlight
◼ Archived
Business
🔮 fades ✓
The Most Powerful Weight Loss Drug Yet Isn’t Approved, but Its Black Market May Already Be Turning Deadly
Black-market weight loss drug linked to 129 symptoms and 2 reported deaths.
◼ Archived
Business
🔮 fades ✓
People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
People with Type 2 diabetes lose up to 60 pounds on Lilly’s latest weight loss drug
◼ Archived
Business
Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug
Eli Lilly is suing six companies to stop illegal sales of its unapproved weight loss drug, retatrutide.
◼ Archived
Business
🔮 fades ✓
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly is suing companies over the illegal sales of its experimental weight-loss drug, retatrutide.
◼ Archived
Health
Is 'Gym Penis' Real? Retatrutide Access Expanded; Vitamin D Fails Cancer Test
The term 'gym penis' is trending online, sparking conversations about male body image and fitness.
◼ Archived
Business
🔮 fades ✓
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
Eli Lilly is expanding access to its experimental obesity drug, Retatrutide, ahead of approval.
◼ Archived
Business
🔮 fades ✗
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly has shifted the FDA application timeline for its next-generation obesity drug, retatrutide, to the first quarter of 2027.
◼ Archived
Business
🔮 fades ✗
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows promising results in weight loss trials, driving stock gains and regulatory anticipation
◼ Archived
Business
🔮 fades ✓
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is advancing toward a 2027 regulatory filing for retatrutide following successful Phase 3 obesity trial results.
◼ Archived
Business
🔮 fades ✓
Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
Speculation swirls around a 79-year-old patient who received an experimental weight loss drug, with former President Trump as the suspected recipient.